Exa-cel 治疗儿童输血依赖型β地中海贫血或镰状细胞病
两项正在进行的3期开放标签单组研究评估了exa-cel在5至11岁输血依赖型β地中海贫血或镰状细胞病儿童中的疗效与安全性。截至至少16个月随访,8例可评估的地中海贫血患儿均实现输血独立,8例可评估的镰状细胞病患儿均无血管闭塞危象;所有患儿均发生至少1起3或4级不良事件,2例地中海贫血患儿发生严重肝静脉闭塞病(与白消安预处理相关),其中1例死亡。
要点
- Exa-cel使可评估的输血依赖型β地中海贫血患儿实现输血独立。
- Exa-cel使可评估的镰状细胞病患儿免于血管闭塞危象。
- 所有患儿均发生3或4级不良事件,预处理相关肝静脉闭塞病可致死。
核心结论
- Exa-cel治疗使随访至少16个月的输血依赖型β地中海贫血患儿实现输血独立、镰状细胞病患儿免于严重血管闭塞危象。
- 所有接受exa-cel的患儿均发生至少1起3或4级不良事件。
研究设计与样本
- 两项正在进行的3期、开放标签、单组研究,评估exa-cel在5至11岁输血依赖型β地中海贫血或镰状细胞病儿童中的疗效与安全性。
- 共15例输血依赖型β地中海贫血患儿和11例镰状细胞病患儿接受了exa-cel输注。
- 输注前接受药代动力学剂量调整的白消安清髓预处理。
- 主要终点:输血依赖型β地中海贫血患儿连续至少12个月输血独立;镰状细胞病患儿连续至少12个月无严重血管闭塞危象。
主要发现
- 输血依赖型β地中海贫血患儿中位随访16.0个月(范围2.2至32.1),镰状细胞病患儿中位随访16.9个月(范围7.6至33.1)。
- 随访至少16个月的8例输血依赖型β地中海贫血患儿均实现输血独立,其余7例尚不可评估。
- 随访至少16个月的8例镰状细胞病患儿均无血管闭塞危象,其余3例尚不可评估。
- 所有患儿均发生至少1起3或4级不良事件;2例输血依赖型β地中海贫血患儿发生严重肝静脉闭塞病,评估与白消安预处理相关,其中1例死亡。
临床怎么用
- 对于5至11岁输血依赖型β地中海贫血或镰状细胞病患儿,exa-cel可能实现输血独立或免于严重血管闭塞危象。
- 需充分评估白消安预处理相关严重肝静脉闭塞病风险,并加强监测。
局限性
- 两项研究均为开放标签、单组设计,无对照。
- 部分患儿随访未达16个月,疗效状态尚不可评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Exagamglogene autotemcel (exa-cel) is a cell therapy in which autologous CD34+ hematopoietic cells are engineered through ex vivo clustered regularly interspaced short palindromic repeats-Cas9 editing of the erythroid-specific enhancer region of BCL11A to express fetal hemoglobin. In phase 3 studies involving participants 12 to 35 years of age with sickle cell disease or transfusion-dependent β-thalassemia, exa-cel eliminated vaso-occlusive crises and the need for red-cell transfusions. METHODS: In two ongoing, phase 3, open-label, single-group studies, we evaluated exa-cel in children 5 to 11 years of age with transfusion-dependent β-thalassemia or sickle cell disease. Before exa-cel infusion, participants underwent myeloablative conditioning with pharmacokinetically dose-adjusted busulfan. The primary end points were transfusion independence for at least 12 consecutive months in children with transfusion-dependent β-thalassemia and freedom from severe vaso-occlusive crises for at least 12 consecutive months in children with sickle cell disease. RESULTS: A total of 15 children with transfusion-dependent β-thalassemia and 11 with sickle cell disease received exa-cel; median follow-up was 16.0 months (range, 2.2 to 32.1) and 16.9 months (range, 7.6 to 33.1), respectively. Of 8 children with transfusion-dependent β-thalassemia who were followed to at least 16 months, 8 were transfusion independent; the status of the remaining 7 was not yet evaluable. Of 8 children with sickle cell disease who were followed to at least 16 months, 8 were free of vaso-occlusive crises; the status of the remaining 3 was not yet evaluable. All the children had at least one grade 3 or 4 adverse event; 2 children with transfusion-dependent β-thalassemia had severe veno-occlusive liver disease that was assessed as being related to busulfan conditioning, 1 of whom died. CONCLUSIONS: Exa-cel therapy resulted in transfusion independence or freedom from severe vaso-occlusive crises in participants with transfusion-dependent β-thalassemia or sickle cell disease, respectively, who were followed for at least 16 months. All the participants had grade 3 or 4 adverse events. (Funded by Vertex Pharmaceuticals and CRISPR Therapeutics; CLIMB THAL-141 ClinicalTrials.gov number, NCT05356195; CLIMB SCD-151 ClinicalTrials.gov number, NCT05329649.).
引用
- Frangoul H, de la Fuente J, Chopra Y, et al. Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease. N Engl J Med. 2026. PMID: 42274009. doi:10.1056/NEJMoa2603387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。